Evidence mapPaperPMID 41239426Full record

ArticleJournal of translational medicine2025

MPTP mediated Ox-mtDNA release inducing macrophage pyroptosis and exacerbating MCD-induced MASH via promoting the ITPR3/Ca

Qi Zhang, Li Chen, Jun-Yan Liu, Tao Liu, Rui Wang, Xin-Yi Wu, Sheng-Wei Li

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qi ZhangDepartment of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Li ChenClinical Medicine and Surgery, The First Affiliated Hospital of Dali University, Yunnan, China.
Jun-Yan LiuDepartment of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Tao LiuRehabilitation Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Rui WangDepartment of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xin-Yi WuDepartment of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. 1121790213@qq.com.
Sheng-Wei LiDepartment of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. lishengwei@hospital.cqmu.edu.cn.ORCID 0000-0002-1647-1363

Funding

Natural Science Foundation of Chongqing Municipality CSTB2022NSCQ-MSX0091
6 · The paper itself

Abstract

backgroundMetabolic Dysfunction-Associated Steatohepatitis (MASH) is a severe and progressive form of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), with approximately 25% of adults worldwide suffering from MASLD, of which 20%-30% progress to MASH, and the global incidence continues to rise. Oxidized mitochondrial DNA (Ox-mtDNA) release is a key contributor to MASH. However, its underlying mechanism remains unclear. Clarifying this process may provide a theoretical foundation for MASH treatment.

methodsIn this study, we separately established MASH models using methionine- and choline deficient diet (MCD) fed mice in vivo and free fatty acid (FFA)-stimulated THP-1 derived macrophages in vitro. Cyclosporin A (CsA: mitochondrial permeability transition pore, mPTP, channel inhibitor) was used to inhibit the release of Ox-mtDNA. 8-OH-dG detection and fluorescent probe were used to evaluate Ox-mtDNA release. Liver lipid deposition was analyzed by Triglyceride (TG) and Oil Red O, and tissue damage were analyzed by aspartate transaminase and alanine aminotransferase (ALT, AST) and H&E staining. Pyroptosis markers, such as cleaved-Caspase1, GSDMD-N, and inflammatory cytokines, such as interleukin - 1β, interleukin 18 (IL-1β, IL-18), were detected by WB, ELISA and transmission electron microscopy (TEM) experiments, and the key pyroptosis pathways activated by Ox-mtDNA were screened by RNA-seq. Finally, ITPR3 was silenced by siRNA in vitro and by Adeno-associated virus (AAV) in vivo respectively, which confirmed the role of ITPR3/Ca

resultsThe cytosolic Ox-mtDNA level was significantly increased during MASH. Inhibition of Ox-mtDNA release alleviated macrophage pyroptosis to improve the pathological phenotype of MASH. RNA-seq analysis showed that cytosolic Ox-mtDNA triggered an inflammatory response by activating the NOD-like receptor pathway, in which FFA induced upregulation of inositol 1,4,5-Trisphosphate Receptor Type 3 (ITPR3, IP3R) expression, and Inhibition of Ox-mtDNA release could relieve this effect. ITPR3 silencing significantly reduced Ca²⁺ release, which in turn inhibited nucleotide-binding domain and leucine-rich repeat protein-3 (NLRP3) inflammasome activation and macrophage pyroptosis. Cytosolic Ox-mtDNA promotes Ca²⁺ release by upregulating ITPR3, activates NLRP3-dependent macrophage pyroptosis, and ultimately exacerbates liver injury and MASH progression.

conclusionsThis study demonstrates that Ox-mtDNA drives MASH progression by promoting macrophage pyroptosis via the ITPR3/Ca²⁺/NLRP3 axis, providing a novel therapeutic strategy for targeted intervention.

Indexed as

CalciumDNA, MitochondrialFatty LiverInositol 1,4,5-Trisphosphate ReceptorsMacrophagesMitochondrial Membrane Transport ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinPyroptosisSignal TransductionAnimalsCholineHumansMaleMethionineMiceMice, Inbred C57BLCalciumCholineDNA, MitochondrialInositol 1,4,5-Trisphosphate ReceptorsMethionineMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreNLR Family, Pyrin Domain-Containing 3 ProteinCa2+ITPR3MASHNLRP3Ox-mtDNAPyroptosis

Identifiers

PMID41239426
PMCPMC12619475

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.